Extrahepatic malignancies and antiviral drugs for chronic hepatitis B: A nationwide cohort study
Clinical and Molecular Hepatology · 2024
DOI: 10.3350/cmh.2024.0055 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Clinical and Molecular Hepatology, 2024. Verfasst von Moon Haeng Hur und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Seoul, Korea. Hauptthemen laut MEDLINE: Antiviral Agents, Hepatitis B, Chronic, Tenofovir, Guanine. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0). Gefördert von: National IT Industry Promotion Agency, Ministry of Science and ICT, Liver Research Foundation of Korea.
Abstract (Originalsprache)
Background/Aims: Chronic hepatitis B (CHB) is related to an increased risk of extrahepatic malignancy (EHM), and antiviral treatment is associated with an incidence of EHM comparable to controls. We compared the risks of EHM and intrahepatic malignancy (IHM) between entecavir (ETV) and tenofovir disoproxil fumarate (TDF) treatment.
Methods
Using data from the National Health Insurance Service of Korea, this nationwide cohort study included treatment-naïve CHB patients who initiated ETV (n=24,287) or TDF (n=29,199) therapy between 2012 and 2014. The primary outcome was the development of any primary EHM. Secondary outcomes included overall IHM development. E-value was calculated to assess the robustness of results to unmeasured confounders.
Results
The median follow-up duration was 5.9 years, and all baseline characteristics were well balanced after propensity score matching. EHM incidence rate differed significantly between within versus beyond 3 years in both groups (P
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Seoul, Korea.
- Department of Internal Medicine, Seoul Metropolitan Government Seoul National University Boramae Medical Center, Seoul, Korea.
- Genome Insight Inc., San Diego, CA, USA.
- Medical Research Collaborating Center, Seoul National University Hospital, Seoul, Korea.
Förderung
- National IT Industry Promotion Agency
- Ministry of Science and ICT
- Liver Research Foundation of Korea
- Seoul National University Hospital
- Yuhan Pharmaceuticals
- GreenCross Cell
- Samjin Pharmaceuticals
- Daewoong Pharmaceuticals
Zitieren
APA
Hur, M. H., Lee, D. H., Lee, J. H., Kim, M. S., Park, J., Shin, H., Chung, S. W., Cho, H. J., Park, M. K., Jang, H., Lee, Y. B., Yu, S. J., Lee, S. H., Jung, Y. J., Kim, Y. J., & Yoon, J. H. (2024). Extrahepatic malignancies and antiviral drugs for chronic hepatitis B: A nationwide cohort study. Clinical and Molecular Hepatology. https://doi.org/10.3350/cmh.2024.0055
Vancouver
Hur MH, Lee DH, Lee JH, Kim MS, Park J, Shin H, et al. Extrahepatic malignancies and antiviral drugs for chronic hepatitis B: A nationwide cohort study. Clinical and Molecular Hepatology. 2024. doi:10.3350/cmh.2024.0055
BibTeX
@article{Hur2024,
author = {Hur, Moon Haeng and Lee, Dong Hyeon and Lee, Jeong-Hoon and Kim, Mi-Sook and Park, Jeayeon and Shin, Hyunjae and Chung, Sung Won and Cho, Hee Jin and Park, Min Kyung and Jang, Heejoon and Lee, Yun Bin and Yu, Su Jong and Lee, Sang Hyub and Jung, Yong Jin and Kim, Yoon Jun and Yoon, Jung-Hwan},
title = {Extrahepatic malignancies and antiviral drugs for chronic hepatitis B: A nationwide cohort study},
journal = {Clinical and Molecular Hepatology},
year = {2024},
doi = {10.3350/cmh.2024.0055}
}
EUVIMED